Adult: 600 mg daily in 2-3 divided doses, may be increased up to a Max of 1,200 mg daily if necessary. Max: 400 mg per dose. Use the lowest effective dose for the shortest possible duration. Elderly: Initiate at the lower end of the dosage range.
Oral Pain and inflammation associated with musculoskeletal and joint disorders, Primary dysmenorrhoea
Adult: For the symptomatic relief of dysmenorrhoea, osteoarthritis or rheumatoid arthritis: 600-900 mg daily in 2-3 divided doses, may be increased up to a Max of 1,200 mg daily if necessary. Max: 400 mg per dose. Use the lowest effective dose for the shortest possible duration. Elderly: Initiate at the lower end of the dosage range.
Renal Impairment
Mild to moderate: Dose reduction is required. Severe: Contraindicated.
Hepatic Impairment
Mild to moderate: Dose reduction is required. Severe: Contraindicated.
Administration
Dexibuprofen May be taken with or without food.
Contraindications
Hypersensitivity to dexibuprofen. History of asthma, urticaria or allergic-type reactions to aspirin or other NSAIDs (including COX-2 inhibitors); history of gastrointestinal tract haemorrhage or perforation due to previous NSAID therapy; active or history of recurrent peptic ulcer or haemorrhage (≥2 distinct episodes of proven ulceration or bleeding); cerebrovascular bleeding or other active bleedings; severe haematologic abnormality; severe heart failure; active Crohn's disease or ulcerative colitis. Use in the setting of CABG surgery. Severe renal and hepatic impairment. Pregnancy (3rd trimester).
Special Precautions
Patient with current or history of bronchial asthma, seasonal allergic rhinitis, nasal congestion (e.g. nasal polyps), COPD or chronic respiratory infections; haemorrhagic diathesis and other coagulation disorders; history of gastrointestinal disease (e.g. ulcerative colitis, Crohn’s disease), gastric cancer; hypertension, ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, CHF (NYHA II-III), oedema; risk factors for CV disease (e.g. hyperlipidaemia, diabetes mellitus, smoking); SLE, mixed connective tissue disorders; porphyria hepatica; alcoholism. Patients undergoing surgery. May mask signs or symptoms of infection. Mild to moderate renal and hepatic impairment. Elderly. Pregnancy (1st and 2nd trimester) and lactation. Concomitant use with aspirin, anticoagulants, oral corticosteroids, and SSRIs.
Adverse Reactions
Significant: Sodium and fluid retention, changes in blood pressure, palpitations, Kounis syndrome, prolonged bleeding time, elevated transaminase levels, hyperkalaemia, drowsiness, dizziness, blurred or diminished vision; aseptic meningitis (particularly in patients with SLE or mixed connective tissue disorder); renal effects (e.g. renal papillary necrosis, interstitial nephritis, nephrotic syndrome, acute renal failure); severe cutaneous adverse reactions (e.g. erythema multiforme, Stevens-Johnson syndrome, SLE, toxic epidermal necrolysis); anaphylactic/anaphylactoid reactions; impairment of female fertility (reversible). Rarely, severe blood dyscrasias (e.g. agranulocytosis, thrombocytopenia, aplastic anaemia). Ear and labyrinth disorders: Vertigo, tinnitus. Gastrointestinal disorders: Dyspepsia, abdominal pain, diarrhoea, nausea, vomiting. General disorders and administration site conditions: Fatigue. Nervous system disorders: Headache. Psychiatric disorders: Insomnia, restlessness, anxiety. Respiratory, thoracic and mediastinal disorders: Rhinitis. Skin and subcutaneous tissue disorders: Rash, urticaria, pruritus. Potentially Fatal: CV thrombotic events (e.g. MI, stroke); gastrointestinal ulceration, bleeding and perforation; severe bronchospasm. Rarely, severe hepatic reactions (e.g. fulminant hepatitis, liver necrosis, hepatic failure).
Patient Counseling Information
This drug may cause drowsiness, dizziness and blurred vision, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor CBC, urinalysis, complete metabolic panel, LFTs and renal function (particularly during chronic use); blood pressure. Assess for bleeding or bruising, gastrointestinal effects (e.g. dyspepsia, occult blood loss), weight gain, oedema, and for signs of hypersensitivity reactions or worsening infection.
Overdosage
Symptoms: Abdominal pain, nausea, vomiting, drowsiness, headache, nystagmus, tinnitus, lethargy, ataxia, hypotension, hypothermia, gastrointestinal bleeding, seizures, impaired kidney function, adult respiratory distress syndrome, metabolic acidosis, and coma. Management: Symptomatic and supportive treatment. Administer activated charcoal if a significant amount is ingested. Gastric emptying by emesis may be considered within 60 minutes of ingestion. In case potentially life-threatening amounts of dexibuprofen were taken, may perform gastric lavage within 60 minutes of ingestion.
Drug Interactions
Enhanced antiplatelet effect with thrombolytics, ticlopidine and other antiplatelet agents. May increase serum concentrations of methotrexate, lithium, digoxin, and phenytoin. May diminish the antihypertensive effect of β-blockers, ACE inhibitors, ARBs, and diuretics. Increased risk of nephrotoxicity with ciclosporin, tacrolimus, sirolimus, and aminoglycosides. May increase the risk of hyperkalaemia or acute renal failure with ACE inhibitors or ARBs. Potentially Fatal: Increased risk of gastrointestinal ulceration and haemorrhage with other NSAIDs (including COX-2 inhibitors), aspirin, anticoagulants (e.g. warfarin), oral corticosteroids, and SSRIs.
Food Interaction
May increase the risk of gastrointestinal bleeding with alcohol.
Action
Description: Mechanism of Action: Dexibuprofen is the S(+)-enantiomer of ibuprofen that has antipyretic, analgesic, and anti-inflammatory properties. It reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2), thereby reducing prostaglandin precursor formation. Pharmacokinetics: Absorption: Well absorbed mainly from the small intestine. Time to peak plasma concentration: 2.1 hours (fasting); 2.8 hours (after a high-fat meal). Distribution: Enters breastmilk. Plasma protein binding: 99.4%, mainly to albumin. Metabolism: Metabolised in the liver via hydroxylation and carboxylation into inactive metabolites. Excretion: Mainly via urine (90%); bile. Elimination half-life: 1.8-3.5 hours.
Chemical Structure
Dexibuprofen Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 39912, Dexibuprofen. https://pubchem.ncbi.nlm.nih.gov/compound/Dexibuprofen. Accessed Aug. 27, 2025.
Sign Out
Continue with Google